Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag in Inoperable or Persistent/Recurrent CTEPH
NCT03689244Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of selexipag in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Actelion Pharmaceuticals Ltd. Started Jan 2019; status: terminated.
02
Drugs
selexipag
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT03689244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03689244.